Clinical experience with Flebogamma® 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease

@article{Ballow2009ClinicalEW,
  title={Clinical experience with Flebogamma{\textregistered} 5\% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease},
  author={M. Ballow},
  journal={Clinical \& Experimental Immunology},
  year={2009},
  volume={157}
}
  • M. Ballow
  • Published 2009
  • Medicine
  • Clinical & Experimental Immunology
The development of effective, safe, liquid intravenous immunoglobulins (IVIG) preparations has represented a major therapeutic advancement in the treatment of patients with antibody deficiencies. Flebogamma® 5% was the first liquid IVIG licensed in Europe that has been widely used in the treatment of immunodeficiency diseases. It has been proven to have an excellent efficacy and safety profile. Flebogamma® 5% dual inactivation and filtration (DIF) is a newly developed IVIG preparation that… Expand
Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients
Primary antibody deficiency syndromes
  • P. Wood
  • Medicine
  • Current opinion in hematology
  • 2010

References

SHOWING 1-10 OF 18 REFERENCES
Safety of IGIV therapy and infusion-related adverse events
Intravenous immunoglobulins: clinical experience and viral safety.
  • M. Ballow
  • Medicine
  • Journal of the American Pharmaceutical Association
  • 2002
The use of intravenous immune globulin in immunodeficiency diseases.
...
1
2
...